260 related articles for article (PubMed ID: 28751663)
1. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies.
Gopal S; Xu H; McQuarrie K; Savitz A; Nuamah I; Woodruff K; Mathews M
NPJ Schizophr; 2017 Jul; 3(1):23. PubMed ID: 28751663
[TBL] [Abstract][Full Text] [Related]
2. Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate.
Lencer R; Garcia-Portilla MP; Bergmans P; Gopal S; Mathews M; Wooller A; Pungor K
Compr Psychiatry; 2021 May; 107():152233. PubMed ID: 33711781
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies.
Savitz AJ; Xu H; Gopal S; Nuamah I; Mathews M; Soares B
Braz J Psychiatry; 2019; 41(6):499-510. PubMed ID: 30994855
[TBL] [Abstract][Full Text] [Related]
6. Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study.
Gopal S; Gogate J; Pungor K; Kim E; Singh A; Mathews M
Neuropsychiatr Dis Treat; 2020; 16():681-690. PubMed ID: 32184607
[TBL] [Abstract][Full Text] [Related]
7. [Caregiver burden in relatives of persons with schizophrenia: an overview of measure instruments].
Reine G; Lancon C; Simeoni MC; Duplan S; Auquier P
Encephale; 2003; 29(2):137-47. PubMed ID: 14567165
[TBL] [Abstract][Full Text] [Related]
8. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
9. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
[TBL] [Abstract][Full Text] [Related]
10. Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.
Alphs L; Bossie CA; Sliwa JK; Fu DJ; Ma YW; Hulihan J
Neuropsychiatr Dis Treat; 2013; 9():341-50. PubMed ID: 23493643
[TBL] [Abstract][Full Text] [Related]
11. Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia.
Garcia-Portilla MP; Llorca PM; Maina G; Bozikas VP; Devrimci-Ozguven H; Kim SW; Bergmans P; Usankova I; Pungor K
Ther Adv Psychopharmacol; 2020; 10():2045125320926347. PubMed ID: 32518617
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
Najarian D; Sanga P; Wang S; Lim P; Singh A; Robertson MJ; Cohen K; Schotte A; Milz R; Venkatasubramanian R; T'Jollyn H; Walling DP; Galderisi S; Gopal S
Int J Neuropsychopharmacol; 2022 Mar; 25(3):238-251. PubMed ID: 34791283
[TBL] [Abstract][Full Text] [Related]
13. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.
Russu A; Savitz A; Mathews M; Gopal S; Feng Y; Samtani MN
J Clin Psychopharmacol; 2019; 39(6):567-574. PubMed ID: 31688450
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study.
Giron-Hernandez C; Han JH; Alberio R; Singh A; García-Portilla MP; Pompili M; Knight RK; Richarz U; Gopal S; Antunes J
Neuropsychiatr Dis Treat; 2023; 19():895-906. PubMed ID: 37077705
[TBL] [Abstract][Full Text] [Related]
16. Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice.
Lopez A; Rey J
Neuropsychiatr Dis Treat; 2019; 15():449-456. PubMed ID: 30804673
[TBL] [Abstract][Full Text] [Related]
17. Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review.
Edinoff AN; Doppalapudi PK; Orellana C; Ochoa C; Patti S; Ghaffar Y; Cornett EM; Kaye AJ; Viswanath O; Urits I; Kaye AM; Kaye AD
Front Psychiatry; 2021; 12():699748. PubMed ID: 34621193
[TBL] [Abstract][Full Text] [Related]
18. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
Schreiner A; Aadamsoo K; Altamura AC; Franco M; Gorwood P; Neznanov NG; Schronen J; Ucok A; Zink M; Janik A; Cherubin P; Lahaye M; Hargarter L
Schizophr Res; 2015 Dec; 169(1-3):393-399. PubMed ID: 26431793
[TBL] [Abstract][Full Text] [Related]
19. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.
El Khoury AC; Pilon D; Morrison L; Shak N; Vermette-Laforme M; Amos TB; Kim E; Lefebvre P
Curr Med Res Opin; 2019 Mar; 35(3):395-405. PubMed ID: 30526125
[TBL] [Abstract][Full Text] [Related]
20. Telehealth-Based Psychoeducation for Caregivers: The Family Intervention in Recent-Onset Schizophrenia Treatment Study.
Mueser KT; Achtyes ED; Gogate J; Mancevski B; Kim E; Starr HL
JMIR Ment Health; 2022 Apr; 9(4):e32492. PubMed ID: 35436231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
